Close Menu

NEW YORK (GenomeWeb) – MDxHealth reported today that its fourth quarter revenues rose 68 percent percent year over year, driven largely by higher sales of its ConfirmMDx prostate cancer test.

For the three months ended Dec. 31, 2015, MDxHealth reported revenues of $5.7 million compared to $3.4 million in Q4 2014.

Sales of the ConfirmMDx test represented 86 percent of the quarter's total revenues compared to 70 percent of revenues in Q4 2014. The increase was also due in part to royalty and milestone payments from Exact Sciences.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.